United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 4 mg - tizanidine tablets are a short-acting drug for the management of spasticity. because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see dosage and administration). concomitant use of tizanidine with fluvoxamine or with ciprofloxacin, potent inhibitors of cyp1a2, is contraindicated. significant alterations of pharmacokinetic parameters of tizanidine including increased auc, t1/2 , cmax, increased oral bioavailability and decreased plasma clearance have been observed with concomitant administration of either fluvoxamine or ciprofloxacin. this pharmacokinetic interaction can result in potentially serious adverse events (see warnings and clinical pharmacology: drug interactions). tizanidine tablets are contraindicated in patients with known hypersensitivity to tizanidine or its ingredients.

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg - tizanidine tablets are a short-acting drug for the management of spasticity. because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see dosage and administration ). concomitant use of tizanidine with fluvoxamine or with ciprofloxacin, potent inhibitors of cyp1a2, is contraindicated. significant alterations of pharmacokinetic parameters of tizanidine including increased auc, t1/2, cmax, increased oral bioavailability and decreased plasma clearance have been observed with concomitant administration of either fluvoxamine or ciprofloxacin. this pharmacokinetic interaction can result in potentially serious adverse events (see warnings and clinical pharmacology: drug interactions ). tizanidine tablets are contraindicated in patients with known hypersensitivity to tizanidine or its ingredients.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg - tizanidine is a short-acting drug for the management of spasticity. because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see dosage and administration ). concomitant use of tizanidine with fluvoxamine or with ciprofloxacin, potent inhibitors of cyp1a2, is contraindicated. significant alterations of pharmacokinetic parameters of tizanidine including increased auc, t1/2 , cmax , increased oral bioavailability and decreased plasma clearance have been observed with concomitant administration of either fluvoxamine or ciprofloxacin. this pharmacokinetic interaction can result in potentially serious adverse events (see warnings and clinical pharmacology: drug interactions ).   tizanidine tablets are contraindicated in patients with known hypersensitivity to tizanidine or its ingredients. abuse potential was not evaluated in human studies. rats were able to distinguish tizanidine from saline in a standa

United States - English - NLM (National Library of Medicine)

proficient rx lp - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 4 mg - tizanidine is a short-acting drug for the management of spasticity. because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see dosage and administration ). concomitant use of tizanidine with fluvoxamine or with ciprofloxacin, potent inhibitors of cyp1a2, is contraindicated. significant alterations of pharmacokinetic parameters of tizanidine including increased auc, t1/2 , cmax , increased oral bioavailability and decreased plasma clearance have been observed with concomitant administration of either fluvoxamine or ciprofloxacin. this pharmacokinetic interaction can result in potentially serious adverse events (see warnings and clinical pharmacology: drug interactions ).   tizanidine tablets are contraindicated in patients with known hypersensitivity to tizanidine or its ingredients. abuse potential was not evaluated in human studies. rats were able to distinguish tizanidine from saline in a standa

United States - English - NLM (National Library of Medicine)

quality care products, llc - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg - tizanidine tablet is a central alpha-2-adrenergic agonist indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine tablets should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration (2.1) ]. tizanidine hydrochloride is contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxacin [see drug interactions ( 7.1, 7.2 ) ]. pregnancy category c tizanidine hydrochloride has not been studied in pregnant women. tizanidine hydrochloride should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. reproduction studies performed in rats at a dose of 3 mg/kg, equal to the maximum recommended human dose on a mg/m2 basis, and in rabbits at 30 mg/kg, 16 times the maximum recommended human dose on a mg/m2 basis, did not show evidence of teratogenicity. tizanidine at doses that are equal to and up to 8 times the maximu

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 4 mg - tizanidine tablet is a central alpha-2-adrenergic agonist indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine tablets should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration ( 2.1) ]. tizanidine hydrochloride is contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxacin [see drug interactions ( 7.1, 7.2 ) ]. pregnancy category c tizanidine hydrochloride has not been studied in pregnant women. tizanidine hydrochloride should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. reproduction studies performed in rats at a dose of 3 mg/kg, equal to the maximum recommended human dose on a mg/m 2 basis, and in rabbits at 30 mg/kg, 16 times the maximum recommended human dose on a mg/m 2 basis, did no

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg - tizanidine tablet is a central alpha-2-adrenergic agonist indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine tablets should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration (2.1 ) ]. tizanidine hydrochloride is contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxain [see drug interactions (7.1, 7.2) ].  tizanidine hydrochloride has not been studied in pregnant women. tizanidine hydrochloride should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. reproduction studies performed in rats at a dose of 3 mg/kg, equal to the maximum recommended human dose on a mg/m2  basis, and in rabbits at 30 mg/kg, 16 times the maximum recommended human dose on a mg/m2 basis, did not show evidence of teratogenicity.  tizanidine at doses that are equal to and up to 8 times the maximum recommended human d

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg - tizanidine tablet is a central alpha-2-adrenergic agonist indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine tablets should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration (2.1) ]. tizanidine hydrochloride is contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxacin [see drug interactions ( 7.1, 7.2 ) ]. pregnancy category c tizanidine hydrochloride has not been studied in pregnant women. tizanidine hydrochloride should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. reproduction studies performed in rats at a dose of 3 mg/kg, equal to the maximum recommended human dose on a mg/m2 basis, and in rabbits at 30 mg/kg, 16 times the maximum recommended human dose on a mg/m2 basis, did not show evidence of teratogenicity. tizanidine at doses that are equal to and up to 8 times the maximu

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg - tizanidine is a central alpha-2-adrenergic agonist indicated for the management of spasticity. because of the short duration of therapeutic effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important [see dosage and administration (2.1)]. tizanidine is contraindicated in patients taking potent inhibitors of cyp1a2, such as fluvoxamine or ciprofloxacin [see drug interactions (7.1, 7.2)]. pregnancy category c   tizanidine has not been studied in pregnant women. tizanidine should be given to pregnant women only if the benefit outweighs the risk to the unborn fetus. reproduction studies performed in rats at a dose of 3 mg/kg, equal to the maximum recommended human dose on a mg/m 2 basis, and in rabbits at 30 mg/kg, 16 times the maximum recommended human dose on a mg/m 2 basis, did not show evidence of teratogenicity. tizanidine at dos

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - tizanidine hydrochloride (unii: b53e3nmy5c) (tizanidine - unii:6ai06c00gw) - tizanidine 2 mg - tizanidine tablets are a short-acting drug for the management of spasticity. because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see dosage and administration ). concomitant use of tizanidine with fluvoxamine or with ciprofloxacin, potent inhibitors of cyp1a2, is contraindicated. significant alterations of pharmacokinetic parameters of tizanidine including increased auc, t1/2, cmax, increased oral bioavailability and decreased plasma clearance have been observed with concomitant administration of either fluvoxamine or ciprofloxacin. this pharmacokinetic interaction can result in potentially serious adverse events (see warnings and clinical pharmacology: drug interactions ). tizanidine tablets are contraindicated in patients with known hypersensitivity to tizanidine or its ingredients. there are no adequate and well-controlled studies to document the safety and efficacy of tizanidin